International Application No PCT/GB2004/004783

A. CLASSII IPC 7	FICATION OF SUBJECT MATTER A61K39/39 A61P9/00 A61P37/	00 A61P37/06								
According to	International Patent Classification (IPC) or to both national classific	ation and IPC								
	SEARCHED									
Minimum do IPC 7	cumentation searched (classification system followed by classificati $A61\text{K}$	on symbols)								
	ion searched other than minimum documentation to the extent that s									
	ata base consulted during the international search (name of data ba	se and, where practical, search terms used)								
EPO-Internal, BIOSIS, EMBASE, WPI Data										
C. DOCUMENTS CONSIDERED TO BE RELEVANT										
Category °	Citation of document, with indication, where appropriate, of the rel	evant passages	Relevant to claim No.							
х	WO 03/049752 A (INSTITUT PASTEUR NATIONAL DE LA SANTE ET DE LA RE MED) 19 June 2003 (2003-06-19) page 4, lines 22-27 page 6, lines 5-8 claims 1,3,5,15,16	; INSTITUT CHERCHE	1-8, 11-19,23							
A	AU 706 122 B2 (UNIVERSITY COLLEG 10 June 1999 (1999-06-10) page 4, lines 3-22; claims 1-3,9 examples 2,4		1-23							
	·	-/ ·								
X Furti	ner documents are listed in the continuation of box C.	Patent family members are listed	n annex.							
"A" docume consid	tegories of cited documents : ent defining the general state of the art which is not lered to be of particular relevance tocument but published on or after the International	"T" later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention								
filing d "L" docume which citation "O" docume other of	late Int which may throw doubts on priority claim(s) or is cited to establish the publication date of another n or other special reason (as specified) ant referring to an oral disclosure, use, exhibition or means	cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.								
later th	ent published prior to the international filing date but an the priority date claimed	*8" document member of the same patent family								
	actual completion of the international search 3 June 2005	Date of mailing of the international search report								
		Authorized officer	Λ7 7005							
I Name and n	nailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Noë, V								

International Application No
PCT/GB2004/004783

		PCT/GB2004/004783
	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	CONFORTI ANITA ET AL: "Specific and long-lasting suppression of rat adjuvant arthritis by low-dose Mycobacterium butyricum" EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 324, no. 2-3, 1997, pages 241-247, XP002319250 ISSN: 0014-2999 abstract	1,5-7, 12,14, 17-19
A	WO 85/05034 A (UNIVERSITY COLLEGE LONDON; YEDA RESEARCH AND DEVELOPMENT CO. LTD) 21 November 1985 (1985-11-21) abstract page 2, lines 3-9 page 2, lines 15-22 page 5, line 24 - page 6, line 7 claims 1,6,10	1-23
P,X	WO 2004/022093 A (UNIVERSITY COLLEGE LONDON; MCINTYRE, GRAHAM; STANFORD, JOHN, LAWSON; S) 18 March 2004 (2004-03-18) the whole document	1-23

International application No. PCT/GB2004/004783

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X Claims Nos.: 24-25 because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 12-25 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. X Claims Nos.: 24-25 because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically: See FURTHER INFORMATION sheet PCT/ISA/210
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
see additional sheet
As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. X As only some of the required additional search fees were timely pald by the applicant, this International Search Report covers only those claims for which fees were pald, specifically claims Nos.:
1-23(partially)
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark on Protest The additional search fees were accompanied by the applicant's protest. X No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-23 (partially)

use of an immune modulator composition comprising a whole cell bacterium from the genus Rhodococcus for the treatment or prevention of autoimmune diseases or disorders

2. claims: 1-23 (partially)

use of an immune modulator composition comprising a whole cell bacterium from the genus Gordonia for the treatment or prevention of autoimmune diseases or disorders

3. claims: 1-23 (partially)

use of an immune modulator composition comprising a whole cell bacterium from the genus Nocardia for the treatment or prevention of autoimmune diseases or disorders

4. claims: 1-23 (partially)

use of an immune modulator composition comprising a whole cell bacterium from the genus Dietzia for the treatment or prevention of autoimmune diseases or disorders

5. claims: 1-23 (partially)

use of an immune modulator composition comprising a whole cell bacterium from the genus Tsukamurella for the treatment or prevention of autoimmune diseases or disorders

6. claims: 1-23 (partially)

use of an immune modulator composition comprising a whole cell bacterium from the genus Nocardioides for the treatment or prevention of autoimmune diseases or disorders

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box II.1

Although claims 12-25 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Continuation of Box II.2

Claims Nos.: 24-25

Claims 24-25 do not have additional technical features and therefore, these claims were not searched

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guideline C-VI, 8.5), should the problems which led to the Article 17(2) declaration be overcome.

Information on patent family members

International Application No PCT/GB2004/004783

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
WO 03049752	Α	19-06-2003	AU BR	2002356387 0214902	Α	23-06-2003 30-11-2004
			CA	2469334		19-06-200
			EP	1461054		29-09-2004
			WO	03049752	A2	19-06-200
AU 706122	B2	10-06-1999	AT	151641		15-05-199
			AT	192046		15-05-2000
			AU	675421		06-02-1997
			AU AU	3637793 7188796		13-09-1993 06-02-1993
			BG	99054		28-08-199
			BR	9305946		21-10-199
			CA	2130117		02-09-199
			CZ		A3	15-02-199
			DE	69309915	D1	22-05-1997
			DE	69309915		24-07-1997
			DE	69328503		31-05-2000
			DE		T2	24-08-2000
			DK DK	630259 763361	T3	15-09-1997 07-08-2000
			EP	0630259		28-12-199
			EP	0763361		19-03-1997
			ËS		T3	01-10-1997
			ĒŠ		Ť3	16-07-2000
			WO	9316727		02-09-1993
			GR		T3	31-10-1997
			GR	3033772		31-10-2000
			HU	69941		28-09-199
			JP KR	7506093 275862	T D1	06-07-199! 15-12-200
			NO	943082		17-10-1994
			NZ	249518		27-07-199
		•	RO		В	30-08-2002
			RU	2124367		10-01-199
		•	SK	99994		10-05-199
			US	5885588	Α	23-03-199
wo 8505034	A	21-11-1985	ΑT	55252		15-08-1990
			AU	588809		28-09-198
			ΑU	4297685		28-11-198
			DE EP	3579113 0181364		13-09-1990 21-05-1980
			WO	8505034		21-11-198
			JP	7051509		05-06-199
			ĴΡ	61502258		09-10-198
			US	4716038		29-12-198
WO 2004022093	 A	18-03-2004	AU	2003263319	A1	29-03-2004
	••		CA	2497644		18-03-2004
			ΕP	1534330	A1	01-06-200
			WO	2004022093	Δ1	18-03-2004